Loading…
Company disclosed the results on January 10, 2025.
Invivyd, Inc. (Nasdaq: IVVD) announced on January 10, 2025, that its product PEMGARDA™ (pemivibart) demonstrated continued neutralizing activity against the dominant SARS-CoV-2 variant XEC.
The announcement provided details on the efficacy of PEMGARDA™ in neutralizing the specified variant, highlighting the product's potential in addressing evolving viral strains.
As of the latest data, Invivyd has a free float of 117,543,000 shares and 233,123,000 shares outstanding.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.